health
EMA Recommends Rasonque for Previously Treated Pancreatic Cancer
The EMA’s human medicines committee recommended EU marketing authorisation for Rasonque, an oral treatment for adults with previously treated metastatic pancreatic adenocarcinoma. In a phase 3 study reported by EMA, median overall survival was 12.4 months with Rasonque and 6.7 months with chemotherapy.